...was Sequana, which was conducting genetic studies in the isolated population of Tristan da Cunha. Sequana... ...now known as Axys (AXPH). But AXPH subsequently sold off the population genomics side of Sequana's...
...Axys Pharmaceuticals Inc. - then Arris Pharmaceutical Corp. - acquired toolkit company Sequana Therapeutics Inc. in 1997 for... ...AXPH announced that it will sell its positional cloning programs located in San Diego, where Sequana... ...cloning programs, which represented 75 percent of Sequana's operations. In the meantime, AXPH is keeping Sequana's...
...genetic studies (including use of the Tristan da Cunha population) through its 1998 acquisition of Sequana... ...genetic studies (including use of the Tristan da Cunha population) through its 1998 acquisition of Sequana...
...San Francisco, Calif. Business: Autoimmune/Inflammation, Drug discovery Departing: Kevin Kinsella, former president and CEO of Sequana Therapeutics Inc....
...was Sequana, which was conducting genetic studies in the isolated population of Tristan da Cunha. Sequana... ...now known as Axys (AXPH). But AXPH subsequently sold off the population genomics side of Sequana's...
...Axys Pharmaceuticals Inc. - then Arris Pharmaceutical Corp. - acquired toolkit company Sequana Therapeutics Inc. in 1997 for... ...AXPH announced that it will sell its positional cloning programs located in San Diego, where Sequana... ...cloning programs, which represented 75 percent of Sequana's operations. In the meantime, AXPH is keeping Sequana's...
...genetic studies (including use of the Tristan da Cunha population) through its 1998 acquisition of Sequana... ...genetic studies (including use of the Tristan da Cunha population) through its 1998 acquisition of Sequana...
...San Francisco, Calif. Business: Autoimmune/Inflammation, Drug discovery Departing: Kevin Kinsella, former president and CEO of Sequana Therapeutics Inc....